$11.36
3.32%
Nasdaq, Fri, Sep 06 2024
ISIN
US82835W1080
Symbol
SBTX
Sector
Industry

Silverback Therapeutics Target price 2024 - Analyst rating & recommendation

Silverback Therapeutics Classifications & Recommendation:

Buy
100%

Silverback Therapeutics Price Target

Target Price $24.33
Price $11.36
Potential
Number of Estimates 3
3 Analysts have issued a price target Silverback Therapeutics 2025 . The average Silverback Therapeutics target price is $24.33. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 4 analysts: 4 Analysts recommend Silverback Therapeutics to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Silverback Therapeutics stock has an average upside potential 2025 of . Most analysts recommend the Silverback Therapeutics stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 0.03 4.13
97.73% 13,650.00%
Net Margin -184,186.00% -1,504.04%
2,782.76% 99.18%

4 Analysts have issued a sales forecast Silverback Therapeutics 2024 . The average Silverback Therapeutics sales estimate is

$4.1m
Unlock
. This is
725.00% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$8.7m 1,640.00%
Unlock
, the lowest is
$2.0m 300.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $30.0k 97.73%
2024
$4.1m 13,650.00%
Unlock
2025
$55.0m 1,233.94%
Unlock
2026
$166m 201.35%
Unlock
2027
$265m 60.09%
Unlock
2028
$439m 65.33%
Unlock

2 Silverback Therapeutics Analysts have issued a net profit forecast 2024. The average Silverback Therapeutics net profit estimate is

$-62.0m
Unlock
. This is
36.17% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-58.2m 27.65%
Unlock
, the lowest is
$-65.9m 44.68%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-55.3m 34.48%
2024
$-62.0m 12.28%
Unlock
2025
$-66.4m 7.03%
Unlock
2026
$-33.4m 49.64%
Unlock
2027
$13.6m 140.58%
Unlock
2028
$50.4m 271.48%
Unlock

Net Margin

2023 -184,186.00% 2,782.76%
2024
-1,504.04% 99.18%
Unlock
2025
-120.68% 91.98%
Unlock
2026
-20.17% 83.29%
Unlock
2027
5.11% 125.33%
Unlock
2028
11.49% 124.85%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.57 -0.64
34.48% 12.28%
P/E negative
EV/Sales 213.98

2 Analysts have issued a Silverback Therapeutics forecast for earnings per share. The average Silverback Therapeutics <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.64
Unlock
. This is
36.17% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.60 27.66%
Unlock
, the lowest is
$-0.68 44.68%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.57 34.48%
2024
$-0.64 12.28%
Unlock
2025
$-0.69 7.81%
Unlock
2026
$-0.35 49.28%
Unlock
2027
$0.14 140.00%
Unlock
2028
$0.52 271.43%
Unlock

P/E ratio

Current -24.39 1,473.55%
2024
-17.75 27.22%
Unlock
2025
-16.58 6.59%
Unlock
2026
-32.93 98.61%
Unlock
2027
81.14 346.40%
Unlock
2028
21.85 73.07%
Unlock

Based on analysts' sales estimates for 2024, the Silverback Therapeutics stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

213.98
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
266.97
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1,765.36
2024
213.98 87.88%
Unlock
2025
16.04 92.50%
Unlock
2026
5.32 66.82%
Unlock
2027
3.33 37.54%
Unlock
2028
2.01 39.52%
Unlock

P/S ratio

Current
2024
266.97 87.88%
Unlock
2025
20.01 92.50%
Unlock
2026
6.64 66.82%
Unlock
2027
4.15 37.54%
Unlock
2028
2.51 39.52%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today